1. Home
  2. Health Information
  3. Pharmaceutical Services
  4. Attention deficit hyperactivity disorder in adults: Application for authority to prescribe Dexamphetamine or Methylphenidate
Print this page Reduce font size Increase font size

Attention deficit hyperactivity disorder in adults: Application for authority to prescribe Dexamphetamine or Methylphenidate

Summary

Under Section 28 of the Poisons and Therapeutic Goods Act 1966, the authority of the NSW Ministry of Health is required to prescribe for, or supply to, any person any preparation of dexamphetamine or methylphenidate.


An Application for Authority to Prescribe a Dexamphetamine or Methylphenidate - Form 1AA - is to be used for the purposes of applying for an authority from the Ministry to prescribe for an adult with Attention Deficit Hyperactivity Disorder.


The prescribing of CNS stimulant medication for the treatment of Attention Deficit Hyperactivity Disorder is to be in accordance with the latest version of TG 190, Criteria for the Diagnosis and Management of Attention Deficit Hyperactivity Disorder in Adults


Form 1AA may be completed electronically using Adobe Reader. (The latest version of Adobe Reader can be downloaded for free from Adobe).  Save the form to a local hard drive before typing in details.


Completed forms are to be faxed to Pharmaceutical Services on (02) 98595175 or posted to Pharmaceutical Services, NSW Ministry of Health, PO Box 103, Gladesville NSW 1675.


For assistance or further information telephone the Monitoring and Compliance Section, Pharmaceutical Services, during business hours on (02) 98795239.

File link: Attention deficit hyperactivity disorder in adults: Application for authority to prescribe Dexamphetamine or Methylphenidate
File Format: PDF
File size: 142Kb
Type: Form
Date of Publication: 23 January 2012
Author Branch: Pharmaceutical Services

Attention deficit hyperactivity disorder in adults: Application for authority to prescribe Dexamphetamine or Methylphenidate
Print this page Reduce font size Increase font size

This web page and associated resource are managed and authorised by Pharmaceutical Services of Clinical Safety, Quality and Governance of the NSW Department of Health. Last updated: 1 March, 2012